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A cost-utility analysis of a rehabilitation service for
people living with and beyond cancer
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Abstract
Background: We conducted a wait-list control randomised trial of an outpatient rehabilitation service for people
living with and beyond cancer, delivered in a hospice day care unit. We report the results of an economic evaluation
undertaken using the trial data.
Methods: Forty-one participants were recruited into the study. A within-trial stochastic cost-utility analysis was undertaken
using Monte-Carlo simulation. The outcome measure for the economic evaluation was quality adjusted life years (QALYs).
Costs were measured from the perspective of the NHS and personal social services. Uncertainty in the observed data was
captured through probabilistic sensitivity analysis. Scenario analysis was conducted to explore the effects of changing the
way QALYs were estimated and adjusting for baseline difference in the population. We also explore assumptions about
the length of treatment benefit being maintained.
Results: The incremental cost-effectiveness ratio (ICER) for the base-case analysis was £14,231 per QALY. When QALYs
were assumed to change linearly over time, this increased to £20,514 per QALY at three months. Adjusting the estimate
of QALYs to account for differences in the population at baseline increased the ICER to £94,748 per QALY at three months.
Increasing the assumed length of treatment benefit led to reduced ICERs in all scenarios.
Conclusions: Although the intervention is likely to be cost-effective in some circumstances, there is considerable
uncertainty surrounding the decision to implement the service. Further research, informed by a formal value of
information analysis, would reduce this uncertainty.
Keywords: Cost-utility, Economics, Health economics, Survivorship, Living beyond cancer
Background
More than 2 million people across the UK are currently
living with and beyond cancer. For those who have re-
cently completed active treatments, but for whom cure
remains unlikely, there may be considerable physical and
psychological morbidity [1,2]. Increasingly there is a
trend towards providing palliative care to those who
might still be considering active treatments from oncol-
ogy services to improve symptom control [3,4]. It re-
mains common practice to refer people with cancer to
palliative care specialists when standard therapy has
failed and cure is no longer likely. At the point of refer-
ral estimating prognosis may be difficult [5]. Patients
may typically access the service for more than three
months and the care that is offered is adjusted according
to deteriorating health status. Attendance at day care
services may enable a smooth transition to terminal
care either as a hospice in patient or at home. A
rehabilitation-focussed approach to care aims to improve
quality of survival, helping people adapt to current cir-
cumstances, lead fulfilling lives and function at a mini-
mum level of dependency regardless of life expectancy
[6]. For those with active recurrent progressive disease,
many UK hospices provide out-patient specialist pallia-
tive day therapy. Such care is increasingly offered to not
only to people with cancer but to those with a range
of other advanced, progressive diseases who are ap-
proaching the end of their lives.
Despite a common focus on provision of individually
tailored holistic care, there is variability in the interven-
tions available, ranging from social support to a clinically
oriented service [7]. Specialist palliative care provision in
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hospices within the UK is largely dependent on funding
spearheaded by the voluntary sector and what is avail-
able in any locality will depend on local resources and
availability of staff, premises and equipment. More
specialised services rely on the availability of a multi-
disciplinary team with the necessary skills and training.
Outpatient clinical assessment may be offered by doctors
or clinical nurse specialists. Such consultations may be
used to identify particular supportive care needs and to
agree a care plan that might include sessions delivered
by physiotherapists, counsellors or complementary ther-
apists. In addition, some attendees may benefit from the
support of interaction with others who are faced with
similar health challenges or from group activities such as
relaxation or guidance for the management of symptoms
such as shortness of breath [8].
There is little current evidence on the relative effect-
iveness of different models of day therapy, and little
guidance to inform those setting up new services or con-
sidering how best to use limited available resource for
the maximum benefit of patients [9,10]. Recent reports
that review available qualitative data suggest a positive
impact on quality of life for people receiving hospice day
care [11]. However data reporting the effects on quanti-
tative outcomes are scarce, in part due to the complexity
of services offered and uncertainty over the choice of
appropriate measures [12,13]. Whilst there is some
evidence from a study conducted in 5 centres in SE
England [14] that those receiving hospice day care used
fewer other health care services, there is a lack of re-
search to assess the costs and cost-effectiveness of hos-
pice day care services [15].
Outpatient services provided by hospices as described
above are considered by some to be an effective way of
providing care to patients that addresses both the phys-
ical and psychological needs of patients. We conducted
an RCT that showed an outpatient service was capable
of addressing these needs. We also investigated whether
such a service is cost-effective and this is the focus of
the current report. In reporting the clinical results of the
trial [6] we were restricted by space to describing a
limited economic analysis of the data available at the pri-
mary outcome point of three months from randomisa-
tion (these results are reproduced here in Table 1). In
this study we report in full the methodology and results
of the economic evaluation, in the form of a cost utility
analysis with full probabilistic sensitivity analysis and
scenario analyses.
Methods
This analysis is based on data collected as part of a com-
pleted randomised controlled trial of the effectiveness of a
complex rehabilitation intervention in a DTU for people
with advanced, progressive, recurrent cancer [16]. Ethical
approval for the trial was received from the joint Univer-
sity College London/University College London Hospital
(UCLH) Research Ethics Committee on October 5, 2009,
ref. 09/H0714/46. The trial was registered with ISRCTN
number 22485853. The primary outcome of the trial was
psychological subscale of the Supportive Care Needs Sur-
vey (SCNS) [17].
Data were collected as part of a two-arm, wait-list,
randomised controlled trial of the rehabilitation service
in addition to usual care compared with usual care alone
[16]. Forty-one patients with active, progressive, recur-
rent malignancies were recruited from breast and haem-
atological oncology out-patient clinics at the Royal Free
Hospital (RFH) and University College London Hospital
(UCLH) joint cancer centre London UK, between August
2010 and July 2011. Ninety-three per cent were female
and the median age was 62 years. Thirty-six participants
(20 in the intervention arm, and 16 in the control group)
completed the 3-month follow-up for whom both effect-
iveness and economic outcomes were available. Reasons
for drop out were independent of the intervention and
analysis was performed on complete data.
The rehabilitation intervention
The rehabilitation intervention was developed and defined
using an iterative “plan-do-study-act” approach consistent
with the guidance on developing complex healthcare inter-
ventions outlined by the UK Medical Research Council
[18]. It offers individual clinical assessment, agreed goal set-
ting and a complex package of specialist multi-disciplinary
services including physical and psychological therapies. The
aim is to achieve an agreed date for discharge from the ser-
vice, usually within 3–6 months. Those whose health con-
tinues to deteriorate may not achieve discharge. Details of
the intervention are described in the form of a written
manual, available from the authors.
Table 1 Incremental cost-effectiveness ratio (reproduced from Jones et al., 2012 [16])
Control Intervention Incremental
Cost (95% CI) QALYs (95% CI) Cost (95% CI) QALYs (95% CI) Cost (95%CI) QALYs (95%CI) ICER
£1,590 0.11 £2,544 0.16 £955 0.05 £19,391
(£1,129 - £2,193) (0.058 - 0.157) (£1,890 - £3,482) (0.137 - 0.187) (£82 - £1,975) (0.000 – 0.112)
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Effectiveness of the intervention
The effectiveness of this intervention was evaluated in a
wait-list randomised controlled trial conducted in a large
inner city cancer centre and the results are published
elsewhere [16]. For the trial we chose participants with
active recurrent progressive breast and haematological
cancers because post treatment needs are well docu-
mented for these disease sites. We found that the
outpatient day-therapy rehabilitation approach was sig-
nificantly more effective than usual care alone for the
primary outcome of psychological needs for care as mea-
sured by the Supportive Care Needs Survey [17]. Health-
related quality of life measured using the EQ-5D was
also found to be higher in the treatment group, although
this difference was not significant and the trial was not
powered to detect a difference on the quality of life out-
come measure.
Cost-effectiveness of the intervention
The trial was limited to a three month data collection
phase due to the wait list design, ethical constraints and
restrictions on research funding. In this paper we de-
velop more fully the economic evaluation to a) include a
full probabilistic sensitivity analysis and b) test assump-
tions made about treatment benefit in the deterministic
analysis. We test these assumptions through scenario
analyses focusing on i) the methods used to calculate
quality adjusted life years and ii) the extrapolation of
treatment costs and benefits beyond the initial three
month follow-up period. Our updated results provide
additional information on the likely longer term impact
of the intervention. This is of importance as people with
advanced disease are likely to have on-going supportive
care needs and many will remain within the service for
an extended period. For those that achieve discharge
from the service, it is hoped that any benefits accrued
would be maintained.
A cost-utility analysis of the intervention compared
with usual care was conducted. The main outcome of
interest for the cost-utility analysis was quality of life,
expressed as quality adjusted life years (QALYs) and
measured using the EQ-5D. The EQ-5D is a commonly
used instrument for the measurement of health related
quality of life [19] and is recommended for use in tech-
nology appraisal by the National Institute for Health and
Care Excellence [20]. Although prognosis of participants
was limited, minimum dependency and maximum func-
tion were key components of the primary outcome and
we therefore considered the EQ-5D to be the most
appropriate preference based measure of HRQoL [21].
The analysis was undertaken from both an NHS and a
personal social services perspective. Results are reported
as incremental cost-effectiveness ratios (ICERs) and
cost-effectiveness acceptability curves (CEACs). A CEAC
shows the percentage of simulations in which an inter-
vention is cost-effective (based on the results of the
Monte Carlo simulations) across a range of willingness
to pay per QALY. Costs and benefits were estimated for
the three month trial period in the analysis, thus no dis-
count rate was applied. Prices are given in UK pounds at
2010–2011 values.
The base-case analysis presented is a stochastic cost-
effectiveness analysis [22]. A Monte Carlo process model-
ling 10,000 simulations was performed following the
approach established by O’Hagan and colleagues [23-25].
Parameter uncertainty was reflected in the analysis through
the use of probabilistic sensitivity analysis (PSA) in a
Bayesian framework. Due to the limited data available, an
uninformative prior was assumed [26]. PSA is used to re-
flect the uncertainty inherent in input parameters estimated
from samples of populations. Model parameters are charac-
terised not as point estimates based on measures of central
tendency but as probability distributions. For each simula-
tion in a PSA, an estimate for each parameter is drawn
from the assigned distribution. The individual values sam-
pled from the distributions are then used to estimate the re-
sults of the model for that simulation. The results of all
simulations are then combined to give an overall result.
Details of the mean values and probability distributions es-
timated for each parameter are presented in Table 2.
At three months, participants reported their use of
medical services since baseline using a modified ver-
sion of the Client Service Receipt Inventory CSRI [27].
We collected data primarily on their use of NHS and
hospice services. Commonly accessed services included
general practitioners, physiotherapists, psychologists or
other counsellors, outpatient hospital appointments. Other
services were less frequently accessed and so have been ag-
gregated in the analysis, weighted according to frequency of
access and cost (see Table 2).
Data on costs were derived from the Unit Costs of
Health and Social Care [28]; where publicly available
data were not available, unit costs were obtained from
the hospice where the trial was conducted. The primary
source for unit cost data [28] does not provide estimates
of variability in unit costs. To reflect variation in unit
costs, an adjustment is made to the total cost estimated
for each simulation using the market forces factor used
to calculate local adjustments to NHS tariff prices. An
upper and lower bound for a uniform distribution was
defined to reflect the market forces factor [29]. For each
simulation, a sample from this distribution was used to
weight the expected total cost per patient. Sources for
all unit costs are presented in Table 3. The way in which
variability in costs was accounted for in the model is the
underlying reason that the results presented in Jones
et al. [16] differ from the base-case results presented
here. In our previous estimate, costs were not included
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in the probabilistic sensitivity analysis. We consider the
current analysis reported here to be more robust than
the previous analysis.
Utility values were estimated using the EQ-5D social
tariff for the UK [19] with scores estimated at baseline
and at three month follow-up. In the base-case analysis
as reported elsewhere [16] QALYs were initially calcu-
lated using the a crude mean difference between the
intervention and control group at three months. We test
this assumption in scenario analyses as described below.
Scenario analyses
We conducted a series of scenario-based sensitivity ana-
lyses to explore variation in our results that arise owing
to changes in assumptions made for the base-case ana-
lysis. We explored variations around two key assump-
tions. The first is the manner in which we calculated
QALYs from the trial data. The second assumption we
test is the length of time over which benefit is main-
tained following treatment.
In the analysis reported alongside the clinical trial [16]
we used a crude estimate of benefit, where we simply
calculated the treatment effect in QALYs based on the
difference in utility scores between treatment groups at
three months follow-up. This has the effect of allocating
all benefit arising from treatment immediately at the
start of treatment. While this may be appropriate in
some scenarios, for this rehabilitation intervention it is
likely that this overstates any differences in QALYs be-
tween groups at three months. We therefore explore
two alternative approaches to calculating QALYs.
In the first sensitivity scenario QALYs were calculated
by integrating utility values over time (area under the
curve), based on EQ-5D values at baseline and three
Table 2 Resource use and utility estimates used in economic evaluation (estimated from trial data)
Control Intervention
Mean (s2) Distribution (alpha, beta) Mean (s2) Distribution (alpha, beta)
Utility values 0.447 (0.01) Gamma (29.45, 0.02) 0.654 (0.002) Gamma (48.01, 0.01)
Outpatient appointment 5.75 (1.00) Gamma (32.95, 0.17) 5.16 (0.44) Gamma (61.08, 0.08)
GP appointment 1.56 (0.25) Gamma (9.65, 0.16) 1.00 (0.10) Gamma (10.50, 0.10)
Other NHS services 1.75 (0.39) Gamma (7.85, 0.22) 0.32 (0.03) Gamma (3.90, 0.08)
Counsellor 0.94 (0.34) Gamma (2.56, 0.37) Not applicable Not applicable Not applicable
Physiotherapist 1.81 (1.24) Gamma (2.65, 0.68) Not applicable Not applicable Not applicable
Outpatient Hospice Not applicable Not applicable Not applicable 2.05 (0.07) Gamma (59.26, 0.03)
DTU Attendance Not applicable Not applicable Not applicable 5.20 (1.05) Gamma (25.74, 0.20)
Hospice Physiotherapy Not applicable Not applicable Not applicable 3.55 (0.97) Gamma (12.98, 0.27)
Other hospice services Not applicable Not applicable Not applicable 1.5 (0.21) Gamma (10.82, 0.14)
Table 3 Cost estimates used in economic evaluation
Resource Mean cost/
unit
Unit Resource Mean cost/
unit
Unit
Outpatient
appointment
£152.00 [28] Outpatient attendance Counsellor £44.00 [28] Per hour client contact
GP appointment £32.00 [28] per 12 minute
consultation
Inpatient admission £225.00 [28] NHS cost per bed day
GP home visit £115.00 [28] 25 minute visit (£4.60 per
minute)
Outpatient Hospice £104.40* Per hospice outpatient appt
Practice Nurse £10.00 [28] Per consultation DTU Attendance £139.80* Cost per DTU attendance
District nurse
(home)
£68.00 [28] Per hour home visit Hospice Physiotherapist £18.50 [28] 30 minute consultation
Palliative nurse
(home)
£68.00 [28] Per hour home visit Hospice Other £37.27 [28]* Weighted average of hospice services used
by the intervention group
Occupational
therapist
£51.33 [28] 40 minute consultation Control group other
services
£66.09 [28]* Weighted average of other service use costs
Physiotherapist £18.50 [28] 30 minute consultation Intervention group other
services
£70.42 [28]* Weighted average of other service use costs
Psychologist £81.00 [28] Per hour client contact
*Costs provided by the hospice participating in the study.
Round et al. BMC Health Services Research 2014, 14:558 Page 4 of 11
http://www.biomedcentral.com/1472-6963/14/558
months, and assuming a linear change between mea-
surements [30]. This approach assumes that changes in
outcome accrue gradually over time. We thereafter refer
to this scenario as “area under the curve approach”.
We then adjusted the estimate of QALY difference be-
tween groups to account for differences at baseline. This
second approach takes into account the imbalance be-
tween groups in EQ5D at baseline and how this could
affect the observed difference in QALYs [30]. It can also
increase precision by reducing standard errors of the
difference in QALY estimates. However the adjustment is
based on a linear regression and assumes a normal distri-
bution of the difference in QALYs between groups, which
may not always hold in a small sample. We thereafter refer
to this scenario as “baseline adjusted approach”.
The final scenario we tested was the length of time
over which patients are assumed to derive benefit from
the intervention. The base-case analysis considered
only the period during which patients were active trial
participants. However, an important component of the
intervention is that it aims to enable patients to be dis-
charged from the service, or to reduce their frequency of
attendance through agreed goal-setting. It is expected
that benefit would be maintained for some period of
time following discharge. However, the limited time
frame of the trial follow-up period prevented the collec-
tion of data on patient outcomes following discharge. To
test what might happen, we considered the benefit of
treatment being maintained over three, six and nine
months beyond completion of the follow-up.
Further assumptions were needed about how to esti-
mate benefits at future time points in the absence of
follow-up data beyond three months. We have assumed
that the mean difference in outcomes at the three month
follow-up point was maintained at future time points.
Although it is unlikely that in practice benefit would be
maintained at a constant level between three month
follow-up and one year, there is no evidence on which to
base any additional assumption. Our current assumption
makes no prediction about changes in quality of life
following treatment; rather we assume only that the
difference between the treatment and control groups is
maintained. We consider the implications of this as-
sumption in more detail in the discussion. We also as-
sume that no additional differences in cost arise during
the extended period of analysis. While it is possible that
the intervention could influence resource use beyond
the three month trial period we expect most of the dif-
ference to happened in the first three months when pa-
tients were attending the day therapy unit (DTU). It is
unknown in which direction any longer term difference
would be and we therefore made the assumption of no
difference in resource use between arms after the initial
three month period.
Figure 1 illustrates how different approaches to esti-
mating patient benefit can lead widely differing results
in QALYs used in an analysis.
Results
Resource use
In Table 4 we show a summary of the mean cost for the
key resource use categories for the control and interven-
tion arms. While the study was not powered to detect
differences in resource use, the descriptive results clearly
show that the primary difference in expected cost arises
from attendance at hospice outpatient and day therapy
units. These cost components form part of the interven-
tion and were not available to the control group.
Base-case analysis
Over the trial period of 3 months, the expected mean
difference in cost from the Monte Carlo simulation in
the base-case analysis was £735 (95% Bayesian credible
intervals (CI) £221 to £1,271) and the mean difference in
QALYs was 0.052 (95% CI 0.040 to 0.063). The ICER
of the mean incremental values is £14,231 per QALY
(Table 5).
Scenario analyses
The results of the scenario analyses are presented in
Tables 5 and 6 as well as Figures 1 and 2. Using the area
under the curve approach to estimating QALYs then the
intervention is expected to be cost-effective in 42.9%
and 64.1% of simulations at threshold values of £20,000
and £30,000 respectively at three months, with an ICER
of £20,514 (Table 6). The likelihood of the intervention
being cost-effective increases with the length of time
benefit is expected to be maintained. It rises to 77.4% at
a threshold value of £20,000 when benefit is measured at
six months. If benefit is maintained over 12 months then
at a threshold value of £20,000 the intervention is
expected to be cost-effective in 89.6% of simulations
(Figure 2).
When we calculate QALYs adjusted for baseline differ-
ences in the control and intervention population, the
intervention becomes less likely to be cost-effective
across all time-horizons and threshold values. The esti-
mated ICER at three months is £94,748 (Table 7) and
consequently the intervention is highly unlikely to be
cost-effective when benefit is only gained for three
months, with a probability of being cost-effective of just
3.7% at the £20,000 threshold and 9.5% at the higher
£30,000 threshold (Figure 3). If benefit is maintained for
a total of six months then the intervention reaches a
probability of being cost effective of 29.5% and 45.2% as
threshold values of £20,000 and £30,000. Only where
benefit is maintained for nine months or longer is the
intervention more likely than not to be cost-effective at
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Figure 1 Example of different approaches for calculating QALYs.
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a threshold value of £20,000 per QALY. At nine months
the intervention is cost-effective in 50.2% of simulations
and at 12 months 60.8% of simulations at a threshold
value of £20,000.
Discussion
We report details of a full cost-utility analysis and asso-
ciated sensitivity analyses of a rehabilitation intervention
that has been shown to be clinically effective in a single-
centre randomised controlled trial. Our results demon-
strate two things. First, that the results of the analysis
are sensitive to the method used to estimate QALYs.
This is well supported in the literature (for a discussion
of this, see Manca and colleagues [30]). Second, it is also
clear that the longer treatment benefit is maintained, the
more likely it becomes that the intervention (which is
provided over a short period of time) represents a cost-
effective use of resources. The CEACs in Figures 1 and 2
are used to show in what proportion of the Monte-Carlo
simulations the intervention is expected to have a
greater net-benefit compared with control across a range
of threshold values of the decision maker’s willingness to
pay for a QALY [31]. In England, for the NHS NICE typ-
ically use a threshold range of £20,000 to £30,000 per
QALY when determining whether a treatment is cost-
effective use of resources.
Our results suggest that a standardised hospice based
day therapy intervention has the potential to be cost-
effective, though in the base-case analysis this effect was
marginal with respect to the NICE threshold value of
£20,000 per QALY in England [32]. We have shown that
when QALYs are estimated using the more robust area-
under-the-curve or baseline-adjusted approaches then
the intervention is less likely to be cost-effective at three
months than in our initial crude analysis. However, if the
benefit of the intervention were maintained as intended
following discharge from the service, then the likelihood
of the intervention being cost-effective clearly increases;
as expected, the longer any observed benefit is main-
tained post-treatment, the more likely the intervention is
a cost-effective use of resources. This finding is inde-
pendent of the method used to estimate QALYs.
Although an RCT provides a robust causal estimate of
the intervention effect, a single trial may not provide
sufficient evidence on which to base a decision on cost
effectiveness [33]. For example, trials such as this which
are limited to single centres, small sample sizes or re-
strictions on clinical diagnoses such as cancer types may
not show to what extent the effectiveness of an interven-
tion is transferable to other settings or patient popula-
tions. In addition trial designs, such as wait-list control,
may not include an appropriate time horizon for the
measurement of treatment costs and outcomes, and may
not be designed to consider all relevant treatment alter-
natives [33]. Such limitations are often pragmatic and re-
flect funding restrictions or clinical circumstances. In
this case, caution was exercised due to the ethics of
withholding a potentially beneficial supportive interven-
tion for those with a limited prognosis.
Transferability of results
In addition to the consideration of local factors and con-
text that influence treatment outcomes in a single centre
study, interpreting economic results also requires con-
sideration of patterns of resource use and costs associ-
ated with a single centre. We have tried within this
analysis to improve the transferability of the results to
the wider NHS and other care providers by estimating
costs using nationally reported unit costs and accounting
for potential variation in costs to different providers.
However, it was necessary to use some estimates of costs
taken from the single delivery site. Local variation in
practice, for example referral rates to secondary care or
procedures for avoiding inpatient admissions, can greatly
Table 4 Deterministic mean cost of individual resources
Expected cost
Resource Control Intervention
Outpatient appointment £874 £784
GP appointment £50 £32
Combined other £101 £58
Physiotherapist £34 Not applicable
Counsellor £41 Not applicable
Outpatient hospice Not applicable £214
DTU Attendance Not applicable £727
Total expected cost £1,100 £1,775
Table 5 Base-case results (with Bayesian credible intervals)
Control Intervention Incremental
Base-case Cost QALYs Cost QALYs Cost QALYs ICER
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) £s/
QALY
Benefit as measured at three
months
£1,193 0.112 £1,928 0.164 £735 0.052 £14,231
(£840 to
£1,638)
(0.102 to
0.123)
(£1,481 to
£2,455)
(0.159 to
0.168)
(£221 to
£1,271)
(0.040 to
0.063)
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influence the cost of providing an intervention. Analysis
of data from a larger multi-centre trial would help ad-
dress these limitations.
Benefits over time
Often the pragmatic design of clinical trials limits the
follow-up period for data collection. The most-appropriate
duration of follow-up for clinical outcomes may differ
from those outcomes needed to estimate the long-term
cost-effectiveness of an intervention, even if the observed
cost-effectiveness ratio is trending towards that of the
long-term ICER [34]. It would be ideal, though usually
impractical, to measure any benefits accrued over the life-
time of the participant. In reality, assumptions about lon-
ger term outcomes must usually be made.
In this trial, the three month follow-up period and
the wait list design were enforced for ethical reasons
and data collected are unlikely to reflect the overall
true outcomes for participants with respect to health
related quality of life. It is also unlikely that those who
experienced benefit at the end of the study period will
lose the entirety of that benefit the moment treatment
stops. What is not known is for how long benefit is
maintained and at what rate it is lost (if at all) over
Table 6 Area under the curve scenario analysis (with Bayesian credible intervals)
Control Intervention ICER
Area under the curve analysis Cost QALYs Cost QALYs £s/
QALY(95% CI) (95% CI) (95% CI) (95% CI)
Benefit as measured at three months £1,202 0.120 £1,936 0.156 £20,514
(£842 to £1,631) (0.077 to 0.160) (£1,483 to £2,459) (0.136 to 0.176)
Benefit maintained to six months £1,192 0.231 £1,931 0.312 £8,371
(£837 to £1,630) (0.138 to 0.318) (£1,471 to £2,477) (0.267 to 0.355)
Benefit maintained to nine months £1,196 0.344 £1,931 0.470 £5,224
(£832 to £1,626) (0.199 to 0.475) (£1,481 to £2,460) (0.398 to 0.537)
Benefit maintained to one year £1,198 0.454 £1,931 0.629 £3,815
(£843 to £1,623) (0.247 to 0.623) (£1,476 to £2,469) (0.526 to 0.718)
Figure 2 CEACs of rehabilitation intervention compared to usual care for unadjusted QALY estimates.
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time. In those with advanced cancer, these factors are
likely to be influenced by familiarity with the hospice
out-patient service, confidence in the probable respon-
siveness of the clinical team should the patient re-
present to the service and deterioration in clinical
condition. We have attempted to address this through
a series of scenario analyses that extend treatment
benefit to a maximum of one year. Though this ap-
proach has obvious limitations based on the non-
availability of data, it provides decision makers with
information derived from modelling scenarios likely to
occur beyond the three month trial analysis period
and may aid them in considering whether or not to
implement the intervention.
Alternative treatment options
An additional limitation of the trial from the perspective
of the economic analyst is that it compares only two al-
ternative treatment modalities. In practice, the particular
form of the intervention as practised in the trial is not
the only possible way to organise and deliver rehabilita-
tion services for patients living with advanced cancer. In
determining the effectiveness from a clinical standpoint,
this is appropriate. However it reduces the information
Table 7 Baseline adjusted scenario analysis (with Bayesian credible intervals)
Costs Estimated QALY
difference
ICER
(95%CI)
Baseline adjusted analysis Control Intervention Mean SE £s/QALY
Benefit as measured at three months £1,203 £1,938 0.008 0.009 £94,748
(£865 to £1,615) (£1,540 to £2,394) — —
Benefit maintained to six months £1,202 £1,931 0.023 0.027 £29,835
(£837 to £1,658) (£1,471 to £2,437) — —
Benefit maintained to nine months £1,207 £1,932 0.039 0.046 £18,771
(£868 to £1,626) (£1,534 to £2,389) — —
Benefit maintained to one year £1,205 £1,933 0.054 0.064 £13,400
(£864 to £1,611) (£1,540 to £2,389) — —
Figure 3 CEACs of rehabilitation intervention compared to usual care for adjusted QALY estimates.
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available to decision makers who must determine not
just whether to offer rehabilitation services but how.
Ideally, any future economic evaluation would examine
not just the results of this trial but also include evidence
from any other trials or sources of robust evidence of
day therapy rehabilitation services. However, no other
such services have been tested in an RCT, nor do any
services have robust evidence of effectiveness and so at
present, this evaluation represents the best possible evi-
dence available to decision makers. In Table 4 we pro-
vide some evidence of the expected mean cost for each
category of resource used in the analysis. Service plan-
ners may be able to use such evidence to develop local
day therapy rehabilitation services.
Research considerations for economic evaluations
Caution is required when comparing individual resource
use as in Table 4, as the study population was not suffi-
ciently large to make such comparisons, nor was re-
source use a designated outcome of the trial. Any larger
multi-centre study of this intervention should examine
such potential resource use related outcomes for partici-
pants. It may be useful to explore which component of
the intervention provides the most benefits for its cost.
In practice, for such complex interventions the individ-
ual effect of each component may not be evaluable sep-
arately from the overall effect. In a larger study it would
be possible to explore whether there are participant sub-
groups which might be more likely to benefit from the
intervention. An exploratory analysis of our results sug-
gests that women and those with lymphoma reported
more benefits than other participants, although these
findings are limited by a small sample size.
Another potential concern in economic evaluations is
the risk of bias arising from the use of patient recall
methods for collecting data on service use. Patient recall
methods are commonly used to collect data on patient
service use as part of clinical trials and other prospective
studies. Concern exists that patients may not be able to
recall with sufficient accuracy their contacts with health
services over time [35]. Although the evidence base re-
mains limited [35], some research has shown that recall
periods of up to six months accurately capture patient
resource use [27] The primary alternative to recall
methods is the use a patient diary in which study partici-
pants record health service use on an on-going basis
during the trial period. However, this method is not typ-
ically recommended, as respondent burden is considered
high and the rates of completion are often low [36].
Challenges for health care providers
Both the range of ICERs and the CEAC for the base-
case analysis indicate uncertainty for decision makers
who must choose whether or not the intervention is a
cost-effective use of scarce NHS resources. The within-
trial analysis, based on costs and outcomes measured at
three months, shows that the intervention sits on
the margins of cost-effectiveness. This leaves decision
makers with a good deal of uncertainty – it is as likely
as not that the intervention is cost-effective if there is a
willingness to pay of £20,000 per QALY. When the
length of time that recipients might expect to maintain
benefit from the intervention is extended the ICER de-
creases, though the probability that the intervention is
cost-effective increase only slightly. This reflects the
considerable degree of uncertainty in the trial data
resulting from the small sample size.
When there is such uncertainty over the likely cost-
effectiveness of an intervention decision makers are
faced with the question of whether or not to implement
the intervention [37]. A number of factors beyond the
ICER and CEAC results can influence this decision.
These might include the ways in which a technology or
intervention is delivered, what recipient groups are likely
to be affected by adoption and questions of equity – that
is, whether any recipient groups might be unfairly disad-
vantaged by the decision to adopt an intervention
[38,39]. In the case of the intervention studied here, de-
cision makers may be helped by further data on the
value of treatment to recipient sub-groups and the ways
in which the intervention can be delivered in different
settings. In addition decision makers must consider the
irreversibility of their decision and the consequences of
a wrong decision [40]. In the case of a day therapy re-
habilitation service, the establishment of such a service
is likely to have few irreversible consequences in circum-
stances where capital investment requirements are likely
to be low and staff training requirements minimal as
specialist multi-disciplinary practitioners are usually
available within hospice settings. Services could be re-
duced easily if further research shows that treatment is
not cost-effective and resources redirected with relative
ease.
Conclusion
Our analyses reveal uncertainty about whether the re-
habilitation intervention represents a cost-effective use
of health care resources when compared with usual care.
Although commissioners may wish to consider introdu-
cing such day therapy services in view of the clinical
benefits to patients, they should be mindful of the need
for further evaluation of cost-effectiveness. This should
be weighed against a) the potential benefits to recipients
and b) the relative ease with which a decision could be re-
versed if the model used follows closely that used in the
RCT on which this evaluation is based [30]. Where a day
therapy service is introduced formal evaluation should
be considered. Value of information analysis would help
Round et al. BMC Health Services Research 2014, 14:558 Page 10 of 11
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determine the benefits and inform the design of such an
evaluation.
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